

Prescient Therapeutics Opens Share Purchase Plan to raise \$7 million Today

Key Highlights:

- Prescient Therapeutics opens Share Purchase Plan (SPP) to raise up to \$7 million (before costs).
- Eligible shareholders will be able to acquire new shares at an issue price of \$0.065 (6.5 cents) per share, representing an 18.8% discount to 10-day VWAP, without incurring brokerage or transaction fees.
- SPP follows a year of strong operational delivery including Phase 2a clinical trial progress.
- Funds raised will be used to advance PTX-100 beyond the Dose Optimisation Committee meeting targeted for the second half of calendar 2026 - and progression into the next stage of development.
- Please join CEO James McDonnell for a live shareholder briefing on Friday, 28th August 11am (AEST). Register here:
<https://prescienttherapeutics.investorportal.com.au/shareholder-briefing-spp/>

MELBOURNE Australia, 26 August 2026 – Prescient Therapeutics (ASX: PTX) (**PTX** or the **Company**), a clinical-stage oncology company developing targeted cancer therapies, is pleased to announce that the Share Purchase Plan (**SPP**), to raise up to \$7 million (**Offer**), opens today. The proceeds from the SPP will support the ongoing development of the Company's first-in-class cancer treatment, PTX-100, allowing the Company to advance its targeted therapy beyond the Dose Optimisation Committee review targeted for the second half of calendar 2026 - an important checkpoint ahead of the Company's subsequent Dose Optimisation Committee reviews and progression into the next stage of development. The program aims to progress, subject to clinical results, toward regulatory approval and broader patient access in an area of significant unmet medical need.

Funds raised will also go towards general working capital, business development and portfolio management activities - which may include the evaluation of complementary pipeline opportunities - and costs of the offer.

The Company also reserves the right to conduct a follow-on placement to sophisticated and professional investors following completion of the SPP, should demand warrant, further details of which (if applicable) will be separately announced to ASX.

An investment in the Company is speculative and subject to a number of risks, details of which are set out in the SPP Booklet.

Under the SPP new fully paid ordinary shares will be issued at \$0.065 per share, equivalent to an 18.8% discount to the volume weighted average price (**VWAP**) over the 10 trading days before the date the SPP was announced, and a 9.7% discount to the last price.

The Company will offer Eligible Shareholders who were registered shareholders as at 7:00pm (AEST) on Monday, 24th August 2026 (**Record Date**) the opportunity to apply for up to A\$30,000 of new fully paid ordinary shares (**New Shares**) in the Company under the SPP. The SPP is expected to remain open until 5:00pm (AEST) on Tuesday, 8 September 2026. See the attached SPP Booklet for the full offer timetable, including the Record Date, Allotment Date and Quotation Date.

Participate in the Share Purchase Plan

Printed copies of the personalised Share Purchase Plan Application Forms (and accompanying mail out letters) will be dispatched to Eligible Shareholders shortly after the announcement date, however, Eligible Shareholders may access the SPP booklet online from the announcement date and request an electronic copy of their personalised Share Purchase Plan Application Form here: <https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/>

Eligible Shareholders are not required to wait for receipt of printed materials before applying under the SPP.

Reach Markets are the advisers managing the Share Purchase Plan and can be contacted on [1300 805 795](tel:1300805795) or via advisers@reachmarkets.com.au

Join a shareholder briefing

Join the CEO of PTX James McDonnell for a live and interactive shareholder briefing on Friday, 28th August 11am (AEST) where he will discuss the Share Purchase Plan, use of funds and how to participate.

Register here: <https://prescienttherapeutics.investorportal.com.au/shareholder-briefing-spp/>

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com
www.ptxtherapeutics.com

Investor & Media enquiries

Patrick Nelson
Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100 is a first-in-class compound with the ability to block an enzyme that can contribute to cancer growth known as geranylgeranyl transferase-1 (GGTase-1). Blocking this target disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral signaling circuits in cancer cells, leading to their apoptosis (death). Mutations in Ras pathways are believed to be involved in up to 22% of all cancers.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and in a recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T-cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the Phase 2a part of the trial.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from

the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via [LinkedIn](#).

Forward-Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.



25 August 2026

Dear Shareholder

Share purchase plan

On behalf of the Board of Prescient Therapeutics, (ASX: PTX) (**Prescient, PTX or Company**), we are pleased to offer you the opportunity to purchase up to \$30,000 in additional shares in PTX under this share purchase plan (**SPP** or the **Offer**).

An SPP allows the Company to offer existing shareholders the opportunity to participate in the next stage of Prescient's journey as we continue to advance through our Phase 2 clinical trials for our lead asset, PTX-100, without the brokerage costs typically associated with an on-market purchase.

Consistent with our recent clinical trial update¹, with trial sites now open across Australia, US and Italy, patient recruitment is meeting targets and remains on track for the Dose Optimisation Committee meeting in late 2026. The outcome of that Committee's review will be an important milestone for the program and, if positive, could represent a meaningful step toward our longer-term commercialisation objective.²

The Board see that there is a tangible opportunity for us to enter a US\$1.2 billion³ US target market, with several significant milestones in the 12 months ahead. Given promising clinical results to date⁴ and FDA/EMA designations⁵, the Board believes PTX-100 has the potential to become a significant addition to Australia's biotech sector, subject to the risks set out below.

The SPP will be available to shareholders who are on the Company register at 7.00pm (Sydney time) on 24 August 2026 (**Record Date**) and have a registered address in Australia or New Zealand (**Eligible Shareholders**).

The Company is seeking to raise \$7 million under the SPP, however the Company reserves the right to raise more or less than this amount in its absolute discretion. The Board reserves the right to close the Offer early or extend the Offer at its absolute discretion.

As set out in our FY26 Annual Report, released to the market on 21 August 2026, PTX-100 has continued to advance strongly since we last asked for your Shareholder support: enrolment in the PTX-100 Phase 2a trial grew from 1 to 28 patients and the active site network expanded to 12 sites, funded by the \$9.8 million raised in the Company's August 2025 SPP and placement.

The SPP gives Eligible Shareholders the opportunity to purchase additional fully paid ordinary shares in Prescient Therapeutics at \$0.065 per share, which represents a discount of 9.7% to the closing price on 24 August 2026, and a discount of 18.8% to the 10-day VWAP. There are no transaction costs or brokerage costs to participating shareholders.

The proceeds from the SPP will support the ongoing development of the Company's first-in-class cancer treatment, PTX-100, allowing the Company to advance its targeted therapy beyond the Dose Optimisation Committee review

¹ June 2026 Quarterly Update and Appendix 4C dated 27th July 2026.

² As with all clinical development, there is no certainty the review will produce a positive outcome - see Risks, below.

³ DelveInsight: CTCL Market Insight, Epidemiology And Market Forecast – 2034. Based on third-party forecasts and subject to assumptions regarding pricing, treatment duration, competition and reimbursement.

⁴ PTX-100 Phase 1b CTCL sub analysis (7 evaluable patients).

⁵ FDA Fast track Designation for Mycosis Fungoides (MF), Orphan Drug designations in US and EU for T Cell Lymphoma and MF plus Sezary Syndrome respectively.

targeted for the second half of calendar 2026 - an important checkpoint ahead of the Company's subsequent Dose Optimisation Committee reviews and progression into the next stage of development. The program aims to progress, subject to clinical results, toward regulatory approval and broader patient access in an area of significant unmet medical need.

Funds raised will also go towards general working capital, business development and portfolio management activities - which may include the evaluation of complementary pipeline opportunities - and costs of the offer.

Included with this letter is the following material which aims to address any questions you may have about the SPP:

- a. an investment overview, which includes details on pricing, the timetable, intended use of funds and key risks of an investment in the Company; and
- b. SPP terms.

The SPP will close on Tuesday, 8 September 2026 at 5.00pm (Sydney time). Acceptances and payment must be received by our registry, Automic, by the closing date. PTX reserves its right to close the SPP early.

How to participate in the SPP Offer

The SPP is an offer to shareholders who were registered holders of fully paid ordinary shares in Prescient Therapeutics (**Shares**) at 7.00pm (Sydney time) on 24 August 2026 (**Record Date**) with a registered address in Australia or New Zealand (**Eligible Shareholders**). All Eligible Shareholders have the opportunity to participate in the SPP.

Printed copies of the personalised Share Purchase Plan Application Forms (and accompanying mail out letters) will be dispatched to Eligible Shareholders shortly after the announcement date, however, Eligible Shareholders may access the SPP booklet online from the announcement date and request an electronic copy of their personalised Share Purchase Plan Application Form here:

<https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/>

Eligible Shareholders are not required to wait for receipt of printed materials before applying under the SPP.

The SPP opens on Wednesday, 26 August 2026, and will close on Tuesday, 8 September 2026 at 5.00pm (Sydney time). Late applications may be accepted or rejected in the absolute discretion of the Company. The Company also reserves the right to vary the Closing Date without prior notice subject to the Corporations Act and the ASX Listing Rules.

The Company has appointed Reach Markets Pty Ltd as Lead Manager to the Share Purchase Plan. If you have any questions, please contact them on advisers@reachmarkets.com.au or by calling 1300 805 795.

Join a shareholder briefing

Join CEO James McDonnell for an upcoming live and interactive shareholder briefing on behalf of the Board where he will discuss the Share Purchase Plan and use of funds.

Register for a session here:

<https://prescienttherapeutics.investorportal.com.au/shareholder-briefing-spp/>

The board encourages you to consider this opportunity and thanks you for your continued support.

Yours faithfully,

Dr James Campbell
Non-Executive Chair
Prescient Therapeutics

PTX investment overview

Offer details

Issue Price	\$0.065 per New Share		
Record Date	7.00pm (Sydney time) on 24 August 2026		
Closing Date	5.00pm (Sydney time) on 8 September 2026		
Allotment Date	15 September 2026		
Quotation Date	16 September 2026		
Application Amount	Minimum of \$5,000 (Minimum Application Amount) with staged increments detailed below up to a maximum of \$30,000.		
	Option	Value	Number of New Shares
	A	\$5,000	76,923
	B	\$10,000	153,846
	C	\$15,000	230,769
	D	\$20,000	307,692
	E	\$30,000	461,538

Intended use of funds

The proceeds from the SPP will support the ongoing development of the Company's first-in-class cancer treatment, PTX-100, allowing the Company to advance its targeted therapy beyond the Dose Optimisation Committee review targeted for the second half of calendar 2026 - an important checkpoint ahead of the Company's subsequent Dose Optimisation Committee reviews and progression into the next stage of development. The program aims to progress, subject to clinical results, toward regulatory approval and broader patient access in an area of significant unmet medical need.

Funds raised will also go towards general working capital, business development and portfolio management activities — which may include the evaluation of complementary pipeline opportunities — and costs of the offer.

Risks

Before making an investment decision, you should read the SPP terms set out below. PTX considers that the major risks of an investment in PTX include:

- (a) **Technical risks** - the inherent nature of research and development is uncertain. There are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. The Company is mitigating this risk where reasonably possible through diversification of its product pipeline, undertaking rigorous scientific review during the development process, and working with reputable and capable partners and service providers;
- (b) **Future funding risks** - whilst the Directors believe that the funds raised through the SPP may be sufficient for the Company's short-term objectives, the Company's ability to continue on a going concern basis will depend upon securing income through licence(s) or other agreements.

Furthermore, there is risk that the Company may require substantial additional financing in the future to sufficiently fund its operations, research and development;

- (c) **RDTI legislative change risk** - the Company's research and development activities benefit materially from the Australian Government's Research and Development Tax Incentive (RDTI), which has been a material and recurring source of cash inflow. Proposed reforms announced in the 2026-27 Federal Budget (not yet legislated) would, if enacted, apply from income years commencing on or after 1 July 2028 and could reduce the quantum of RDTI benefit available to the Company or restrict access to it as a refundable cash benefit, which could materially affect the Company's future cash flows and ability to fund its research and development programs as currently planned;
- (d) **Regulatory and licensing risks** - if the Company does not obtain the necessary regulatory approvals, it may be unable to commercialise its pharmaceutical products. Even if it receives regulatory approval for any product candidates, profitability will depend on its ability to generate revenues from the sale of its products or the licensing of its technology;
- (e) **Success of future trials** - future clinical trials of the Company's product candidates may not show sufficient safety or efficacy to obtain requisite regulatory approvals for commercial sale;
- (f) **Commercialisation of products** - the Company's ability to achieve profitability is dependent on a number of factors including its ability to initiate and complete successful clinical trials and obtain regulatory approval for its products and successfully commercialise those products. There is no guarantee that the Company's products will be commercially successful;
- (g) **Competition** - the biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. To compete successfully the Company must deliver to the market cost effective products that meet important medical needs;
- (h) **Risk of delay** - the Company may experience delay in achieving a number of critical milestones, securing further commercial partners, development of manufacturing processes, completion of clinical trials, obtaining regulatory approval (to commence sales) or reimbursement approvals (for sales growth), product launch and sales in one or more jurisdictions. Any material delays may impact adversely upon the Company, including the timing of any revenues under milestone or sales payments;
- (i) **Dependence on commercial partners and future licence arrangements** - there is no guarantee that the Company will be able to find suitable industry partners with which it can negotiate attractive commercial terms for future licence agreements for new or its existing products. The success of the Company's partnering arrangements may depend on resources devoted to them by itself or its industry partners. Collaborative agreements may be terminable by the Company's partners. Non-performance, suspension or termination of relevant agreements is likely to have a material and adverse impact on the Company's business, financial condition and results of operations;
- (j) **Reimbursement** - in many territories, products such as those being developed by the Company, must follow a formal reimbursement process in order to be commercially successful. The availability and timing of reimbursement may have an impact upon the uptake and profitability of products in some jurisdictions;
- (k) **Asset impairment value** - the Company has a significant amount of intangible assets recorded on its balance sheet. The Company annually tests the carrying value of these intangible assets for impairment. The estimates and assumptions about results of operations and cash flows made in connection with impairment testing could differ from future actual results of operations and cash flows;

- For personal use only
- (l) **Reliance on key personnel** - the Company's success depends to a significant extent upon its key management personnel, as well as other management and technical personnel including those employed on a contractual basis. The loss of the services of such personnel or the reduced ability to recruit additional personnel could have an adverse effect on the performance of the Company;
 - (m) **Intellectual property** - the Company's ability to leverage its innovation and expertise is dependent on its ability to protect its intellectual property and any improvements to it; and
 - (n) **IT system failure and cyber security risks** - any information technology system is potentially vulnerable to interruption and/or damage from a number of sources, including but not limited to computer viruses, cyber security attacks and other security breaches, power, systems, internet and data network failures, and natural disasters. The Company is committed to preventing and reducing cyber security risks through outsourced IT management to a reputable services provider. In addition, the Company has an insurance policy covering IT and cyber security.

This document may contain forward-looking statements. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond PTX's control, which may cause actual results to differ materially from those expressed or implied in this document.

PTX Share purchase plan terms

How do I accept

To participate, you should pay the Application Amount via BPAY® so that payment is received by **5.00pm (Sydney time) on 8 September 2026**. EFT is also available for overseas holders and for those who are otherwise unable to use BPAY.

BPAY and EFT instructions are set out on the application form. You do not need to return your application form. If paying via BPAY, please make sure you use the specific biller code and reference number on your personalised application form. If paying via EFT, please ensure you use the unique entitlement reference number within the EFT section as your description in order to allow your payment to be allocated to your holding. Your financial institution may implement earlier cut-off times for electronic payment. You should take this into consideration when making payment.

Eligible Shareholders who would like to request an electronic copy of their personalised SPP Offer Application Forms can do so by registering here - <https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/>.

Funds received for applications by BPAY or EFT will be regarded as applications for the maximum number of shares that those funds will pay for in full.

Importantly, while participation in the plan is optional, once applications are submitted, they cannot be withdrawn.

The Company's market price may vary at any time during the offer period and the Company's shares may trade at a price that is lower than the Issue Price.

By accepting the SPP offer, you accept the risk that the market price of the Company's shares may fall below the Issue Price between the date of this offer and the Allotment Date, in which case you may have been able to buy the Shares at a lower price than the Issue Price.

By making an application, you represent to the Company the matters set out under the heading 'Your representations' in these terms and in the application form.

How many shares

Eligible Shareholders receive the number of shares equal to the Application Amount (subject to any scale-back) divided by the Issue Price. Fractions will be rounded down, and the difference (being any amount less than the Issue Price) may be retained by the Company.

The Issue Price does not exceed the limit prescribed by the ASX Listing Rules and ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (**ASIC Instrument 2019/547**).

Shares issued under the SPP may be sold or transferred on ASX at any time after the Quotation Date.

Eligibility to participate

Participation in the SPP is optional. The offer is open to all shareholders with a registered address in Australia or New Zealand as at the Record Date.

Multiple holdings

If you are the only registered holder of Company shares, but you receive more than one offer under the SPP (for example, due to multiple registered holdings), you may only apply in total for a maximum of \$30,000 worth of shares.

Joint holders

If you are a joint holder of Company shares, that holding is considered to be a single registered holding for the purpose of the SPP. You are entitled to participate in the SPP for that single holding only. If you are a joint holder and you receive more than one offer under the SPP, you may only apply in total for a maximum of \$30,000 worth of shares.

Trustee or nominee

If you are noted on the Company's share register as a trustee or nominee for a named beneficiary, you may only apply for one maximum parcel of shares for each named beneficiary. If the Company's share registry does not record a named beneficiary for your trustee or nominee holding, the rules for multiple single holdings apply.

Custodians

If you are a custodian within the definition of 'custodian' in ASIC Instrument 2019/547 (as varied) and hold Company shares for one or more persons (each a **Participating Beneficiary**), or for another custodian of Company shares, you may apply for up to a maximum of \$30,000 worth of shares for each Participating Beneficiary, subject to providing the Company a 'custodian certificate' in addition to the application form, which certifies matters required by ASIC Instrument 2019/547 (as varied).

Please contact the share registry via email on corporate.actions@automicgroup.com.au to obtain the custodian certificate.

Directors

Directors of the Company who are Eligible Shareholders may participate in the SPP.

Scale-back

The Company may, in its absolute discretion, scale-back applications under the SPP.

Factors that the Company may take into account in determining any scale-back include:

- compliance with regulatory requirements, including the ASX Listing Rules and considerations raised by the ASX in its public consultation paper dated 5 April 2022 (**Consultation Paper**) as it applies to appropriate scale-back considerations which the Company may consider in an SPP (section 2.1.1 of the Consultation Paper);
- the date on which a shareholder made its application for shares;
- the amount applied for by each shareholder;

- the number of shares held by a shareholder at the Record Date; and
- if the shareholder remains on the register at the Closing Date.

The Company may scale-back applications below the Minimum Application Amount. Scale-back decisions are made by the board and are final.

If a scale-back occurs, the difference between the value of the shares allotted and the Application Amount paid to the Company (only where the amount is greater than the Issue Price) will be refunded by EFT using the bank details recorded on the Register when processing refunds. Any scale-back will be announced on the Allotment Date. No interest will be paid on any Application Amount paid or refunded.

The ability to scale-back applications under the terms of this document remains available to the Company, including in circumstances where the Company has elected to close the offer early and any such scale-back will not prevent the Company from undertaking a subsequent placement.

ASX quotation

After shares are issued and allotted under the SPP, the Company will apply to ASX for quotation of the shares on the Official List and send an allotment notice to each Eligible Shareholder's registered address.

No costs

Eligible Shareholders may subscribe without incurring brokerage costs, commission or other transaction costs.

Who is the Lead Manager?

The Lead Manager for the SPP and any follow-on placement is Reach Markets Pty Ltd ACN 145 312 232 (**Reach**).

Reach can be contacted on 1300 805 795 or via email at advisers@reachmarkets.com.au.

The Company will pay Reach a 6% fee on funds actually raised from the SPP (which may include any shortfall/follow-on placement, if requested by the Company). In addition, Reach is to receive one option for every 10.71 ordinary shares issued, with an exercise price of \$0.0975 (9.75 cents), expiring

4 years following the issue date. These options are to be issued 14 days following the settlement of the SPP.

Privacy

Potential Applicants who apply for New Securities will provide 'personal information' (within the meaning given to that term in the Privacy Act) to the Company, the Lead Manager and the Share Registry. By applying for New Securities under an Offer, an Applicant will be taken to have consented to the Company, the Lead Manager and the Share Registry collecting, holding and using the Applicant's personal information in order to assess their Application, process the Applications, service their needs as a Shareholder, provide facilities and services that the Applicant requests, and carry out appropriate administrative functions. Corporate and taxation laws require the Company to collect some personal information. Applicants who do not provide the information requested may not have their Application processed efficiently, or at all.

Reach's Privacy Policy can be viewed here - <https://reachmarkets.com.au/privacy/> along with their Financial Services Guide, available here - <https://reachmarkets.com.au/financial-services-guide/>.

The Company's rights

The Company may reject any application for shares under the SPP if:

- it considers that the application does not comply with these terms;
- you are not an Eligible Shareholder; or
- there are grounds for believing that the applicant is not acting in good faith.

The Company may modify, suspend or cancel the SPP at any time. This includes closing the SPP early or extending the Offer as it sees fit. If the Company does this it will notify ASX. If the SPP is cancelled the Application Amount will be refunded without interest. Neither the Company nor the board accepts or assumes any liability to shareholders because of the variation, suspension or termination of the SPP.

The Company may settle, at its discretion in any manner it deems fit, any anomalies or disputes in connection with the SPP and that decision is

conclusive and binding on all applicants. The Company reserves the right to waive strict compliance with these terms.

The Company reserves the right to run a follow-on placement to exempt investors on conclusion of the SPP should there be sufficient demand.

Your representations

By making a BPAY or EFT payment, you:

- certify to the Company that you are an Eligible Shareholder;
- authorise the Company (and its officers and agents) to correct any error in, or omission from, your application form;
- accept the risks of the delivery of any refund to you;
- acknowledge that the Company may at its discretion determine that your application form is valid, even if the application form is invalid;
- confirm you have read and accept all the included risks associated with this offer;
- irrevocably and unconditionally agree to these terms; and
- acknowledge that the Company is not liable for any exercise of its discretions referred to in these terms.

Other information

The Offer is non renounceable, which means that you cannot transfer your right to purchase shares under the SPP to anyone else. Shares issued under the SPP will rank equally in all respects with existing fully paid shares.

This document is not an offer of securities in any place outside Australia or New Zealand and does not take into account your individual investment objectives, financial situation or particular needs. An investment in the Company is speculative. Therefore, you should obtain independent financial and taxation advice before making an investment decision.